Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

237
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
237
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

555
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
555
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.7K
Pneumonia IV: Management01:28

Pneumonia IV: Management

429
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026
Same author

Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.

Journal of clinical medicine·2026
Same author

Lipoid Pneumonia: HRCT and MRI Spectrum, Diagnostic Pitfalls, and Imaging-Based Diagnostic Workflow.

Diagnostics (Basel, Switzerland)·2026
Same author

miR-205-5p drives endothelial dysfunction and senescence in pulmonary fibrosis.

JCI insight·2026
Same author

Sex-Dependent Integration of Symptoms and Functional Vulnerability in Interstitial Lung Disease: eurILDreg Study.

Respiration; international review of thoracic diseases·2026
Same author

Beyond overlap: a Ro52-driven glandular-pulmonary phenotype at the interface of Sjögren disease and anti-synthetase syndrome in a multicentre cohort.

Frontiers in immunology·2026

Related Experiment Video

Updated: Aug 25, 2025

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

11.0K

Developing PI3K Inhibitors for Respiratory Diseases.

E Fagone1, M Fruciano1, E Gili1

  • 1Department of Clinical and Experimental Medicine, Regional Referral Center for Rare Lung Diseases, University Hospital "Policlinico G. Rodolico-San Marco", University of Catania, Catania, Italy.

Current Topics in Microbiology and Immunology
|October 15, 2022
PubMed
Summary
This summary is machine-generated.

Phosphoinositide 3-kinase (PI3K) pathway inhibition shows promise for treating respiratory diseases like asthma and lung cancer. While effective in animal models, further clinical trials are needed to confirm efficacy and safety in humans for conditions including COPD and ARDS.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

21.0K

Related Experiment Videos

Last Updated: Aug 25, 2025

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

11.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K
Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling
05:47

Generation of Human 3D Lung Tissue Cultures 3D-LTCs for Disease Modeling

Published on: February 12, 2019

21.0K

Area of Science:

  • Pharmacology
  • Pulmonology
  • Oncology

Background:

  • The phosphoinositide 3-kinase (PI3K) signaling pathway plays a critical role in the pathogenesis of various respiratory disorders.
  • Experimental models indicate that inhibiting PI3K could be a therapeutic strategy for conditions such as asthma, COPD, IPF, ARDS, and lung cancer.

Purpose of the Study:

  • To review the current therapeutic strategies targeting PI3K inhibition for respiratory diseases.
  • To summarize the progress and challenges of PI3K inhibitor development in different respiratory conditions.

Main Methods:

  • Review of experimental models and ongoing clinical trials involving PI3K inhibitors.
  • Analysis of PI3K pathway's role in the pathophysiology of asthma, COPD, IPF, ARDS, and lung cancer.

Main Results:

  • Selective PI3K delta and gamma inhibitors show efficacy in asthma models.
  • PI3K inhibitors show potential in IPF and lung cancer models, with some trials ongoing for NSCLC and ARDS in COVID-19 patients.
  • Clinical trial data for COPD and asthma remains limited, with mixed results on efficacy despite acceptable safety profiles.

Conclusions:

  • PI3K inhibition is a promising therapeutic avenue for respiratory diseases, but clinical translation is in its early stages.
  • Further research and clinical trials are essential to establish the efficacy and safety of PI3K inhibitors across various respiratory conditions.
  • Targeted delivery, such as PI3K inhibitors bound to FAP ligands for IPF, represents an innovative approach.